Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer (MDX010-21)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00323882
First received: May 8, 2006
Last updated: June 24, 2014
Last verified: June 2014

May 8, 2006
June 24, 2014
February 2005
September 2009   (final data collection date for primary outcome measure)
The primary objective of the study is to determine the safety profile [ Time Frame: varied timepoints ] [ Designated as safety issue: Yes ]
  • The primary objectives of the study are to determine the safety profile;
  • maximum tolerated dose (MTD);
  • and dose-limiting toxicity (DLT) of escalating doses of MDX-010 administered every 3 weeks up to 4 times to patients with HRPC.
Complete list of historical versions of study NCT00323882 on ClinicalTrials.gov Archive Site
  • Provide a preliminary assessment of clinical antitumor activity, including an assessment of prostate-specific antigen (PSA) responses and metabolic bone activity. [ Time Frame: every 12 weeks ] [ Designated as safety issue: No ]
  • Determine whether additional dosing in patients with mixed response or stable disease can elicit an objective response [ Time Frame: every 12 weeks ] [ Designated as safety issue: No ]
The secondary objective is to provide a preliminary assessment of clinical antitumor activity, including an assessment of PSA responses and metabolic bone activity.
Not Provided
Not Provided
 
Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
A Phase I/II, Open-label, Dose-escalation Study of MDX-010 Administered Every 3 Weeks for 4 Doses in Patients With Metastatic Hormone-Refractory Prostate Cancer

Multicenter study in which patients with metastatic hormone refractory prostate cancer (HRPC), who have not had previous chemotherapy or immunotherapy treatments, will receive MDX-010 every 3 weeks for 4 doses (12 weeks total duration). MDX-010 will be administered at escalating dosage levels of 3, 5, 7.5 and 10 mg/kg/dose infusions. At least 6 patients will be enrolled in each dosage level. Patients will be followed for 1 year or until disease progression to assess response. Patients will be followed for survival status for up to 7 years after enrollment. Patients who tolerate and respond to treatment or who have stable disease for 3 months or longer and who subsequently progress during the follow up phase of the study may have the option to receive additional treatment with MDX-010.

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Prostate Cancer
  • Neoplasm Metastasis
Drug: MDX-010
selected dose administered IV every 3 weeks
Experimental: MDX-010
Intervention: Drug: MDX-010
Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014 Apr 2;6(230):230ra45. doi: 10.1126/scitranslmed.3008002.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
66
July 2013
September 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologic diagnosis of adenocarcinoma of the prostate
  • Metastatic prostate cancer (positive bone scan or measurable disease)
  • Total testosterone of greater than 50 ng/dL, except for patients with prior orchiectomy, where testosterone does not need to be measured.
  • Patients who are receiving an antiandrogen as part of primary androgen ablation must demonstrate disease progression following discontinuation of antiandrogen and completion of a washout period and then observe disease progression.
  • Patients must stop using any herbal product known to decrease PSA levels (eg., saw palmetto and PC-SPES) or any systemic or topical corticosteroid at least 4 weeks prior to screening. Progressive disease must be documented after discontinuation of these products.
  • Progressive disease after androgen deprivation (or hormone therapy). For patients with measurable disease, progression will be defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria. For patients with progression in, or without any measurable disease, a positive bone scan and elevated PSA will be required.
  • Patients receiving bisphosphate therapy must have been on stable doses for at least 4 weeks with stable symptoms prior to enrollment.
  • No prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control prostate cancer).
  • Prior radiation therapy completed at least 4 weeks prior to enrollment. No prior radiopharmaceuticals (strontium, samarium) within 8 weeks prior to enrollment.

Exclusion Criteria:

  • Bone pain due to metastatic bone disease severe enough to require routine narcotic analgesic use.
  • History of severe hypersensitivity reactions to drugs formulated with polysorbate 80.
  • Patients with active autoimmune disease or a history of autoimmune disease that required systemic steroids or immunosuppressive medications, except for patients with vitiligo.
  • Prior therapy with any anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) antibody.
  • Active infection requiring therapy.
  • Concurrent medical condition requiring the use of systemic or topical corticosteroids; systemic or topical corticosteroids must be discontinued at least 4 weeks prior to enrollment. The use of inhaled corticosteroids is acceptable.
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00323882
MDX010-21, CA184-017
No
Bristol-Myers Squibb
Bristol-Myers Squibb
Not Provided
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Bristol-Myers Squibb
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP